Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2025-09-26 Report Publication Anno…
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the upcoming release of financial results and the scheduling of an investor conference call. It does not contain the actual financial results or the transcript of the call itself. According to the 'Menu vs Meal' rule, an announcement regarding the timing or publication of a report is classified as a Report Publication Announcement (RPA).
2025-09-26 English
FORM 6-K
Regulatory Filings
2025-09-23 English
Addex Appoints Bank of New York Mellon as Depositary Bank
Regulatory Filings Classification · 100% confidence The document is an 'Ad Hoc Announcement' regarding the appointment of a new ADS depositary agent (BNY Mellon). This is a corporate administrative update that does not fit into specific categories like earnings, dividends, or M&A. Since it is a regulatory announcement regarding company operations/structure that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-09-23 English
FORM 6-K
Regulatory Filings
2025-06-30 English
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Regulatory Filings Classification · 95% confidence The document is titled "Ad Hoc Announcement Pursuant to Art. 53 LR" and details a strategic investment made by Addex Therapeutics in Stalicla, including changes to the board of directors. This type of announcement, which is not a full financial report (like 10-K or IR) but rather a material corporate event disclosure, fits best under the general category for regulatory announcements that don't have a more specific code. While it mentions management changes (CEO appointed to a board), the primary focus is the transaction itself. Since it is an 'Ad Hoc Announcement' and doesn't fit perfectly into specific categories like M&A (TAR) or Management Changes (MANG), the most appropriate fallback category for a general, material regulatory disclosure is Regulatory Filings (RNS). The document length (6461 chars) is substantial enough that it is not merely an announcement *of* a report, but the report itself.
2025-06-30 English
FORM 6-K
Regulatory Filings
2025-06-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.